The 36-month beta value for PDSB is at 1.70. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PDSB is 29.59M, and currently, shorts hold a 18.61% of that float. The average trading volume for PDSB on March 27, 2024 was 788.42K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PDSB) stock’s latest price update
PDS Biotechnology Corporation (NASDAQ: PDSB)’s stock price has decreased by -13.67 compared to its previous closing price of 4.48. However, the company has seen a -19.59% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-20 that PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Following the release, management will host a conference call to review the financial results and provide a business update.
PDSB’s Market Performance
PDSB’s stock has fallen by -19.59% in the past week, with a monthly drop of -36.60% and a quarterly drop of -24.61%. The volatility ratio for the week is 7.04% while the volatility levels for the last 30 days are 8.14% for PDS Biotechnology Corporation The simple moving average for the last 20 days is -26.56% for PDSB stock, with a simple moving average of -26.42% for the last 200 days.
Analysts’ Opinion of PDSB
Many brokerage firms have already submitted their reports for PDSB stocks, with B. Riley Securities repeating the rating for PDSB by listing it as a “Buy.” The predicted price for PDSB in the upcoming period, according to B. Riley Securities is $10 based on the research report published on November 01, 2022 of the previous year 2022.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PDSB reach a price target of $25. The rating they have provided for PDSB stocks is “Overweight” according to the report published on June 28th, 2021.
H.C. Wainwright gave a rating of “Buy” to PDSB, setting the target price at $6 in the report published on November 10th of the previous year.
PDSB Trading at -26.12% from the 50-Day Moving Average
After a stumble in the market that brought PDSB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.34% of loss for the given period.
Volatility was left at 8.14%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -34.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.27% lower at present.
During the last 5 trading sessions, PDSB fell by -20.40%, which changed the moving average for the period of 200-days by -35.11% in comparison to the 20-day moving average, which settled at $5.16. In addition, PDS Biotechnology Corporation saw -22.18% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PDSB
The total capital return value is set at -1.07. Equity return is now at value -143.08, with -77.50 for asset returns.
Based on PDS Biotechnology Corporation (PDSB), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -1.39. The debt to equity ratio resting at 0.96. The interest coverage ratio of the stock is -23.99.
Currently, EBITDA for the company is -40.74 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.21.
Conclusion
In conclusion, PDS Biotechnology Corporation (PDSB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
